Press Releases

Annual Report 2015
19 April 2016
EN FR

Mithra Obtains Three Marketing Authorisations for its Product Tibelia®, one of Which in the United Kingdom Where it Signed a First License and Supply Agreement
13 April 2016
EN FR

FDA Feedback on SPA Estelle®: a New Step Closer to the Launch of Estelle® Phase III Pivotal Clinical Studies
5 April 2016
EN FR

Topline Results of Food Effect Study of the Product Candidate Estelle®, the New Combined Oral Contraceptive Composed of 15 mg of Estetrol (E4) and 3 mg of Drospirenone (DRSP)
1 April 2016
EN FR

Update on Zoreline® Projects Including Last Interim Results for the Pharmacodynamics Study of the 3-­‐Month Implant
31 March 2016
EN FR

Formulation Development of the Product Candidate Myring is Complete, Production of Clinical Batches for the Final Bioequivalence Study can Start
30 March 2016
EN FR

Already 4 European Countries Fully Approved Protocol of MIT-ES001-C301 Estelle Phase III Clinical Study
24 March 2016
EN FR

Mithra’s Tibelia® gets green light for market authorization in 14 European Countries, reinforces its CDMO ​production pipeline and demonstrates its development capabilities
10 March 2016
EN FR

Mithra Unveils its Business Plan to More Than 35 French Journalists in Presence of Roselyne Bachelot, Former France’s Health Minister
9 March 2016
EN FR

Lancering van de website Gyn&co
7 March 2016
FR NL

Press Release: Financial Results 2015
3 March 2016
EN FR

Financial Results 2015
3 March 2016
EN FR